Abstract: The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.
Type:
Grant
Filed:
June 10, 2002
Date of Patent:
August 30, 2005
Assignee:
Bayer HealthCare AG
Inventors:
Jens-Kerim Ergüden, Marcus Bauser, Nils Burkhardt, Dietmar Flubacher, Arno Friedl, Irene Gerlach, Volker Hinz, Reinhard Jork, Paul Naab, Maria Theresia Niewöhner, Thorsten Oliver Repp, Karl-Heinz Schlemmer, Jürgen Stoltefuss, David Brückner, Martin Hendrix, Dagmar Schauss, Adrian Tersteegen, Ulrich Niewöhner
Abstract: The present invention relates to a process for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide starting from 2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)-dione, 4-(4-aminophenyl)-3-morpholinone and 5-chlorothiophene-2-carbonyl chloride.
Type:
Application
Filed:
January 10, 2005
Publication date:
August 18, 2005
Applicant:
Bayer HealthCare AG
Inventors:
Mathias Berwe, Christian Thomas, Joachim Rehse, Dirk Grotjohann
Abstract: The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
Type:
Grant
Filed:
July 17, 2002
Date of Patent:
August 16, 2005
Assignee:
Bayer HealthCare AG
Inventors:
Maria Theresia Niewöhner, Erwin Bischoff, Helmut Haning, Afssaneh Rahbar, Tiemo-Joerg Bandel, Wolfgang Barth, Ulrich Niewöhner
Abstract: Reagents which regulate human transient receptor potential channel and reagents which bind to human transient receptor potential channel gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, urinary incontinence, overactive bladder, benign prostatic hyperplasia, lower urinary tract syndromes, and CNS disorders.
Type:
Application
Filed:
April 10, 2003
Publication date:
August 11, 2005
Applicant:
Bayer HealthCare AG
Inventors:
Masahiro Shiroo, Noriyuki Yamamoto, Fumihiko Hayashi, Johannes Floeckner, Peter Reinemer, Jeffrey Encinas, Shinichi Watanabe, Masaomi Tajimi, Toshio Kokubo
Abstract: The invention provides a human FPRL1 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD, asthma, genito-urological disorders and inflammation diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD, asthma, genito-urological disorders and inflammation diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of FPRL1 as well as pharmaceutical compositions comprising such compounds.
Type:
Application
Filed:
March 21, 2003
Publication date:
July 28, 2005
Applicant:
Bayer HealthCare AG
Inventors:
Stefan Golz, Ulf Bruggemeier, Andreas Geerts
Abstract: The invention relates to novel compounds of formula (I), to a method for the production thereof, and to their use as medicament active ingredients for the prophylaxis and/or treatment of diseases.
Type:
Application
Filed:
January 3, 2003
Publication date:
July 21, 2005
Applicant:
Bayer Healthcare AG
Inventors:
Barbara Albrecht, Michael Gerisch, Michael Harter, Thomas Krahn, Felix Oehme, Karl-Heinz Schlemmer, Henning Steinhagen
Abstract: The present invention relates to chromans, to processes for their preparation and to their use in medicaments, in particular as agents for treating disorders of the central nervous system.
Type:
Grant
Filed:
September 18, 2002
Date of Patent:
July 19, 2005
Assignee:
Bayer HealthCare AG
Inventors:
Dietrich Scherling, Wolfgang Karl, Dietrich Seidel, Corinna Weinz, Rudolf Schohe-Loop, Frank Mauler
Abstract: This invention relates to urea derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The urea derivatives of the present invention has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.
Abstract: The invention relates to novel 1-aza-bicyclic N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
Type:
Application
Filed:
March 3, 2003
Publication date:
July 14, 2005
Applicant:
Bayer Healthcare AG
Inventors:
Joachim Luithle, Frank-Gerhard Boss, Christiana Erb, Katrin Schnizler, Timo Flessner, Marja Kampen, Christoph Methfessel, Frank-Thorsten Hafner
Abstract: Disclosed are novel nucleic acid and amino acid sequences of immune-related proteins. Reagents that bind to immune-related gene products can be used to treat conditions involving inflammatory processes, such as allergy, asthma, autoimmune diseases, and other chronic inflammatory diseases where an over-activation or prolongation of the activation of the immune system causes damage to tissues.
Abstract: The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.
Type:
Application
Filed:
February 14, 2003
Publication date:
June 9, 2005
Applicant:
Bayer Healthcare AG
Inventors:
Udo Stropp, Stephan Schwers, Harald Kallabis
Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
Type:
Grant
Filed:
February 12, 2003
Date of Patent:
May 10, 2005
Assignee:
Bayer Healthcare AG
Inventors:
Maria Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski, Ulrich Niewöhner
Abstract: The invention relates to compounds of general formula (I), to a method for the production thereof, to pharmaceutical compositions containing them, and to their use in the treatment and/or prophlaxis of diseases in humans or animals, diseases. The compounds are derivatives of the natural substances andrimide and moiramide B.
Type:
Application
Filed:
November 7, 2002
Publication date:
April 14, 2005
Applicant:
Bayer HealthCare AG
Inventors:
Nina Brunner, Christoph Freiberg, Thomas Lampe, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Shiffer, Mitsuyuki Shimada
Abstract: The invention relates to nonadepsipeptides and process for their preparation, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.
Type:
Application
Filed:
May 6, 2004
Publication date:
April 7, 2005
Applicant:
Bayer HealthCare AG
Inventors:
Franz Von Nussbaum, Nina Brunner, Sonja Anlauf, Rainer Endermann, Chantal Furstner, Elke Hartmann, Johannes Kobberling, Jacques Ragot, Guido Schiffer, Joachim Schuhmacher, Niels Svenstrup, Joachim Telser, Michael-Alexander Bruning
Abstract: The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
Type:
Application
Filed:
April 26, 2004
Publication date:
March 24, 2005
Applicant:
Bayer HealthCare AG
Inventors:
Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Thomas Lampe, Susanne Nikolic, Jurgen Reefschlager, Rudolf Schohe-Loop, Frank Sussmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jorg Keldenich, Dieter Lang, Peter Nell
Abstract: The invention relates to novel tetrahydroisoquinolines, to processes for their preparation and to their use for producing pharmaceuticals for the treatment and/or prophylaxis of diseases, in particular of states of pain.
Type:
Application
Filed:
September 11, 2002
Publication date:
March 3, 2005
Applicant:
Bayer HealthCare AG
Inventors:
Nils Gribenow, Bernd Kalthof, Heinrich Meier, Stephan-Nicholas Wirtz, Peter Spreyer
Abstract: The invention concerns isotopically coded marker (ICAT) for mass spectrometric analysis of proteins, and the preparation and use of said markers.
Abstract: The present invention relates to novel substituted pyrazole derivatives of the general formula (I)
in which the substituents R1, R2, R3, A, X and Y are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.
Type:
Grant
Filed:
March 26, 2001
Date of Patent:
December 21, 2004
Assignee:
Bayer HealthCare AG
Inventors:
Alexander Straub, Achim Feurer, Cristina Alonso-Alija, Elke Stahl, Johannes-Peter Stasch, Elisabeth Perzborn, Joachim Hütter, Klaus Dembowsky
Abstract: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.
Type:
Application
Filed:
February 10, 2004
Publication date:
December 16, 2004
Applicant:
Bayer HealthCare AG
Inventors:
Rainer Endermann, Harald Labischinski, Christoph Ladel, Uwe Petersen, Ben Newton